Ana Lako
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Lako has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Stafford
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA
28 shared publications - Anita Giobbie-Hurder
Dana-Farber Cancer Institute, Boston, MA
28 shared publications - Charles H. Yoon
Department of Surgical Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
28 shared publications - David J. Mooney
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, USA
28 shared publications - Edward J. Doherty
Attivare Therapeutics Inc
28 shared publications - Emily M. Thrash
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
28 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Lethal prostate cancer has passed through at least two evolutionary bottlenecks: acquisition of metastatic potential and development of castration resistance. A better understanding of how this affects genetic heterogeneity across metastatic sites is needed to develop strategies to block metastatic spread and to overcome resistance. By leveraging deep whole-exome sequencing of 93 tumors from 26 patients, we examined patterns of metastatic dissemination and clonal evolution of prostate cancer. Phylogenetic reconstruction and mathematical modeling enabled quantification of the number of mutations and clones in the cancer ecosystem and characterization of each patient’s disease as an evolutionary process. Although mutations of the earliest pathogenic genetic drivers of prostate cancer were truncal, most other likely passenger mutations, copy-number alterations, and clones arose after the cancer had spread and were confined to individual metastatic sites because of polyclonal and polyphyletic seeding. Single-tissue sequencing tended to overestimate mutation clonality and, apart from truncal drivers, underestimate mutation rates for both individual patients and cohorts. This study highlights the independent evolution of metastatic lesions, which has implications for diagnostic and targeted therapy strategies.Significance:Genomic analysis of a multisite metastatic prostate cancer cohort reveals patterns of clonal heterogeneity, dissemination, and evolution, highlighting the need to evaluate multiple samples to fully characterize the clonal architecture of tumors.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Lethal prostate cancer has passed through at least two evolutionary bottlenecks: acquisition of metastatic potential and development of castration resistance. A better understanding of how this affects genetic heterogeneity across metastatic sites is needed to develop strategies to block metastatic spread and to overcome resistance. By leveraging deep whole-exome sequencing of 93 tumors from 26 patients, we examined patterns of metastatic dissemination and clonal evolution of prostate cancer. Phylogenetic reconstruction and mathematical modeling enabled quantification of the number of mutations and clones in the cancer ecosystem and characterization of each patient’s disease as an evolutionary process. Although mutations of the earliest pathogenic genetic drivers of prostate cancer were truncal, most other likely passenger mutations, copy-number alterations, and clones arose after the cancer had spread and were confined to individual metastatic sites because of polyclonal and polyphyletic seeding. Single-tissue sequencing tended to overestimate mutation clonality and, apart from truncal drivers, underestimate mutation rates for both individual patients and cohorts. This study highlights the independent evolution of metastatic lesions, which has implications for diagnostic and targeted therapy strategies.Significance:Genomic analysis of a multisite metastatic prostate cancer cohort reveals patterns of clonal heterogeneity, dissemination, and evolution, highlighting the need to evaluate multiple samples to fully characterize the clonal architecture of tumors.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Overview of the cohort and ubiquitous alterations across metastatic tumors in mCRPC. A, Overview of the cohort by number of patients and samples obtained from each tissue. B, Patients and their corresponding sequenced tissue sites. Some of the patients might have multiple tumors from the same site. The “other” category includes tissues for which fewer than six tumors are obtained. C, Alteration landscape of the cohort. Likely driver genes, which are commonly altered in prostate cancer and altered at least once in this cohort, are included. LOH is only shown when it is accompanied by a mutation. D, Proportion of patients with alterations in genes recurrently altered in prostate cancer (alterations shown in C). Among CNV alterations, only homozygous deletions and amplifications have been considered. E and F, Proportion of mutations classified as present and clonal in all sites as a function of the number of sites evaluated. E, All patients. F, Patients with at least four sites sequenced. Significance based on the Wilcoxon rank-sum test. G, CCF of mutations in prostate cancer recurrently mutated genes compared with all other detected mutations. Amp, amplification; Avg, average; del, deletion; met, metastasis, Non-Syn, nonsynonymous.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Overview of the cohort and ubiquitous alterations across metastatic tumors in mCRPC. A, Overview of the cohort by number of patients and samples obtained from each tissue. B, Patients and their corresponding sequenced tissue sites. Some of the patients might have multiple tumors from the same site. The “other” category includes tissues for which fewer than six tumors are obtained. C, Alteration landscape of the cohort. Likely driver genes, which are commonly altered in prostate cancer and altered at least once in this cohort, are included. LOH is only shown when it is accompanied by a mutation. D, Proportion of patients with alterations in genes recurrently altered in prostate cancer (alterations shown in C). Among CNV alterations, only homozygous deletions and amplifications have been considered. E and F, Proportion of mutations classified as present and clonal in all sites as a function of the number of sites evaluated. E, All patients. F, Patients with at least four sites sequenced. Significance based on the Wilcoxon rank-sum test. G, CCF of mutations in prostate cancer recurrently mutated genes compared with all other detected mutations. Amp, amplification; Avg, average; del, deletion; met, metastasis, Non-Syn, nonsynonymous.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 6: Matched normal RNA counts
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 6: Matched normal RNA counts
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 5: Tumor RNA counts
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 5: Tumor RNA counts
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 1: Results of the DeTiN indicating tumor in normal contamination
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 1: Results of the DeTiN indicating tumor in normal contamination
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Figure 3: Heterogeneity of recurrent copy number alterations across metastatic sites (supplement)
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Figure 3: Heterogeneity of recurrent copy number alterations across metastatic sites (supplement)
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Figure 2: Mutational heterogeneity in mCRPC and its impact on detecting alterations using a single sample per patient (supplement)
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Figure 2: Mutational heterogeneity in mCRPC and its impact on detecting alterations using a single sample per patient (supplement)
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 8: QC measures for DNA samples
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 8: QC measures for DNA samples
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S13 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 13: List of WA_24 segments with LOH
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Supplementary Table 13: List of WA_24 segments with LOH
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Patterns of clonal evolution and metastatic dissemination in mCRPC. A, Analytic workflow for clonal reconstruction, phylogenetic inference, and analysis of metastatic seeding patterns. Each point represents a mutation. B, Distribution of CCFs (density) within clone types stratified by position in the phylogenetic tree (trunk, branch, and leaf). C, Proportion of clone types by patient. This plot excludes the clones not placed in the trees. D, Proportion of clone types by recurrently mutated genes. This plot excludes the clones not placed in the trees. E, Total number of detected clones as a function of the number of sites profiled. Each colored curve corresponds to an individual patient. MSI, microsatellite instability. F, Number of patients density (y-axis) compared with the average number of leaf clones they harbor. Light green, predicted number; dark green, actual number of leaf clones. G, Proportion of clones detected as increasing numbers of sites are evaluated. The maximal number of clones per-patient corresponds to the asymptote from E. H, Proportion of clones detected as truncal (y-axis) per different number of evaluated sites (x-axis). I and J, Classification of clonal phylogenetic trees based on ancestral relationships between seeding clones. Bolded edges indicate that the descendant clone seeded a new site. Arrows, parallel seeding (bifurcation). K and L, Juxtaposition of clonal phylogenetic trees (left) and clonal migration diagrams (right) for two index cases: WA_22 (K) and WA_32 (L). Clone colors are matched between trees and diagrams. SNV, single-nucleotide variants.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Patterns of clonal evolution and metastatic dissemination in mCRPC. A, Analytic workflow for clonal reconstruction, phylogenetic inference, and analysis of metastatic seeding patterns. Each point represents a mutation. B, Distribution of CCFs (density) within clone types stratified by position in the phylogenetic tree (trunk, branch, and leaf). C, Proportion of clone types by patient. This plot excludes the clones not placed in the trees. D, Proportion of clone types by recurrently mutated genes. This plot excludes the clones not placed in the trees. E, Total number of detected clones as a function of the number of sites profiled. Each colored curve corresponds to an individual patient. MSI, microsatellite instability. F, Number of patients density (y-axis) compared with the average number of leaf clones they harbor. Light green, predicted number; dark green, actual number of leaf clones. G, Proportion of clones detected as increasing numbers of sites are evaluated. The maximal number of clones per-patient corresponds to the asymptote from E. H, Proportion of clones detected as truncal (y-axis) per different number of evaluated sites (x-axis). I and J, Classification of clonal phylogenetic trees based on ancestral relationships between seeding clones. Bolded edges indicate that the descendant clone seeded a new site. Arrows, parallel seeding (bifurcation). K and L, Juxtaposition of clonal phylogenetic trees (left) and clonal migration diagrams (right) for two index cases: WA_22 (K) and WA_32 (L). Clone colors are matched between trees and diagrams. SNV, single-nucleotide variants.